Financials
- Market Capitalization 139.52 B
- Employee 75 K
- Founded N/A
- CEO Albert Bourla
- Website www.pfizer.com
- Headquarter Delaware, United States
- FIGI BBG000BR2B91
- Industry 药品制造—常规
总收入
净利润
每股基本收益(基本 EPS)
总债务
自由现金流
现金及现金等价物
市盈率
18.31
市销率
2.27
每股股息
1.72
股息收益率 %
6.91
Related tickers
| # | 姓名 | 价格 | 24小时 % | 7天 % | 一个月 % | 一年 % | 市值 | 最近7天 | |
|---|---|---|---|---|---|---|---|---|---|
| 70 | AMGN Amgen Inc. - Common Stock | 360.45 USD | -0.81% | -3.70% | +1.46% | +21.28% | 194.54 B USD | ||
| 91 | GILD Gilead Sciences, Inc. - Common Stock | 131.40 USD | +1.21% | -0.92% | +4.95% | +18.35% | 163.14 B USD | ||
| 126 | BMY Bristol-Myers Squibb Company Common Stock | 59.37 USD | +3.14% | +2.73% | +4.16% | +25.68% | 121.24 B USD | ||
| 138 | GSK GSK plc American Depositary Shares | 52.29 USD | -0.95% | -3.38% | -1.23% | +19.25% | 112.83 B USD |
Pfizer, Inc. Common Stock
辉瑞公司(Pfizer Inc.)是一家总部位于纽约市曼哈顿“螺旋大楼”(The Spiral)的美国跨国制药与生物技术企业。该公司由德国企业家查尔斯·辉瑞(Charles Pfizer)和查尔斯·F·埃哈特(Charles F. Erhart)于1849年在纽约创立,是北美历史最悠久的制药公司之一。 辉瑞致力于研发和生产免疫学、肿瘤学、心脏病学、内分泌学及神经病学领域的药物和疫苗。该公司销售额最高的药品包括艾乐妥(Eliquis)、普瑞沃(Prevnar)、帕克斯洛维德(Paxlovid)、维达克(Vyndaqel)、科米纳蒂(Comirnaty)和易布朗斯(Ibrance)。 2025年,该公司59%的收入来自美国,5%来自中国,36%来自其他国家。 在按营收排名的最大生物医学公司榜单中,该公司位列第五。在《财富》500强中排名第69位,在《福布斯》全球2000强中排名第73位。新闻
摩根士丹利基于积极试验数据重申辉瑞制药评级
IP Group 2025财年业绩:净资产值增长13%,辉瑞制药特许权使用费估值1.28亿英镑
辉瑞制药atirmociclib显示癌症进展风险降低40%
葛兰素史克(GSK.US)RSV疫苗获FDA扩大批准 新增2100万成人市场迎战辉瑞竞争
Barclays重申对BridgeBio Pharma股票的增持评级
William Blair首次覆盖BridgeBio股票,给予跑赢大盘评级
BMO重申辉瑞制药股票跑赢大盘评级,基于抗体数据
Ipsen撤回药物后Wolfe Research重申ORIC股票同业表现评级
Hims & Hers股价盘前飙升;辉瑞制药、安捷伦科技下跌
辉瑞制药皮肤病药物试验结果积极,股价仍下跌
辉瑞tilrekimig在皮炎二期试验中达到主要终点
图表与思路
PFE - Daily Trading Forecast
Daily price was bounced from support level at 25.19 to above for 200 SMA to be crossed for the bullish trend to be resumed. Stochastic oscillator is showing the oversold market condition for the price, and Parabolic SAR is on uptrend for the price to be started so the bullish trend continuation is very likely for D1 price for example. if the price breaks 26.54 resistance level to above for the 27.85 possible target so the primary bullish trend will be resumed; If the price crosses support level at 25.19 to below so the bearish reversal will be started with 24.83 as the target to re-enter; alternatively, the price will be on secondary ranging to be near 200 SMA waiting for the direction of the strong trend to be started. Trading Summary : ranging for direction
1 The PFE doesn’t have other trading ideas at this time
Browse ready-made trading ideas or select a symbol and create your own
Go to Charts and Trading Ideas